EGFR and non-small cell lung carcinoma: After the adjustment for within-trial crossover, from the perspective of China's healthcare system, camrelizumab combination therapy was cost-effective as first-line treatment for patients with advanced, non-squamous NSCLC without Alk or Egfr genomic aberrations.